Globus Medical Q2 Results: 56% EPS Jump Hides a Real Slowing Story

The headline split made Q2 look messier than the operating story

The first read on Globus Medical's quarter is confusing: GAAP diluted EPS fell 26.2% while non-GAAP diluted EPS rose 55.8%. Revenue rose just 5.9%. That kind of split almost guarantees a mixed first reaction. Some investors will fixate on the weaker GAAP figure. Others will note that the prior-year comparison was distorted by a Nevro bargain-purchase gain.

The real question is whether the core business has slowed for good

The debate is not which EPS headline is cleaner. It is what kind of business Globus is becoming. Is this a reset point for a once-faster grower, or a solid spine franchise that still has enough momentum in the parts of the business investors care about most?

There is reason for both views. Management said revenue grew 9% excluding Nevro, and the company still generated quarterly free cash flow reached $176.6 million. But 5.9% reported revenue growth is not the kind of top-line stretch that usually drives a high-growth rerating.

That is why this quarter matters. The market now has to decide whether this was just a messy quarter or the start of a lower-growth regime.

Underneath the 6% top-line number, spine held up better than Nevro weighed it down

The useful takeaway is not the 6% headline anymore. It is what sat underneath it.

The core spine business still looks operational

If you strip out Nevro, Globus still delivered 9% growth excluding Nevro. U.S. Spine grew 7%, and International Spine grew 14% as-reported, or 12% on a constant-currency basis. Those are the units investors should treat as the core business because they better reflect case volume, surgeon retention, and share gains in a more normal operating environment.

So investors should be careful not to overread the slowdown. A 6% top-line print can look sleepy next to Globus' older growth profile. But if the spine franchise is still expanding in both the largest unit and the international unit, the slowdown may reflect reporting mix and segment drag more than a meaningful drop in procedure demand.

Why reported revenue can look softer than operating demand

This is where readers can get tripped up. Revenue recognition and sales mix can blunt the topline even when demand is still standing up.

Last quarter, management already flagged a Nevro revenue decline tied to structural changes made within sales and marketing, and said Nevro could get a bit worse before getting better. Q1 also showed a shift toward more leases and rentals in Enabling Technologies, which can weigh on reported revenue without proving weaker product traction.

That is the practical read here: one unit is still acting like a rain cloud, and that can mask a core spine business that is holding up reasonably well. Bears should not treat 6% growth as definitive proof of damaged demand. But they also should not pretend it is the same thing as a healthy high-growth read.

What matters next

The cleanest watchpoint is simple: 9% growth excluding Nevro. If that metric holds, operating momentum is still there. If it slips, the slowdown is broader than Nevro alone.

Profitability improved materially, so the margin story matters as much as the growth deceleration

That is why the argument has shifted from "which EPS number is cleaner?" to whether Globus is converting each dollar of sales into more profit than the market expects.

Why GAAP EPS is less useful in this quarter

GAAP EPS can mislead here because the prior-year baseline was distorted by a $110.5 million bargain-purchase gain. Strip that out, and the operating improvement becomes clearer: GAAP gross margin rose to 66.8%, GAAP operating income more than doubled, adjusted EBITDA margin reached 35.4%, and the company generated quarterly free cash flow reached $176.6 million.

In simple terms, Globus is keeping more cash from each dollar of sales. That matters more than a one-quarter GAAP distortion because valuation follows durable earning power. If profits are rising faster than revenue, the business is getting better at converting case volume into margin, not just selling more.

What likely drove the stronger profit engine

The mechanism is straightforward. Lower cost of sales and tighter spending in several areas lifted the profit pool even with only modest top-line growth. Management also said the quarter included adjusted gross margin expansion of 200 basis points versus a year ago, which suggests the improvement was not just an accounting effect.

Manufacturing improvements could matter more than another revenue burst

This is the part long-term investors should pay closest attention to: management has pointed to a forward 12-18 month in-house manufacturing improvement path. If that plan stays on track, Globus may not need heroic revenue growth to keep lifting margins. That is how a more mature medical-device company starts to deserve a richer multiple: not by pretending every year will be a high-growth story, but by widening the profit pool over time.

What would confirm the bull case

The main risk is a one-quarter effect. If margins improve now but not in the next report, investors should treat this as a reset, not a new plateau. If the profitability improvement repeats, this quarter starts to look more like the beginning of a stronger earnings engine.

GMED stock still needs proof that the core spine engine can do more than hold up

The practical call is straightforward: respect the franchise, but do not let the non-GAAP gap become an excuse to ignore a softer growth read. Bulls should treat the GAAP-versus-non-GAAP split as a bridge, not the thesis. The real question is whether the core spine engine can keep translating case volume into a wider profit pool, starting from 9% growth excluding Nevro and expanded adjusted EBITDA margin.

Bull case vs. bear case

The bull case is that Globus still has the ingredients for a rerating. Management described share gains across a majority of its underlying businesses, with spine still growing and profitability improving. If investors focus more on durable earnings power than on a headline clouded by a bargain-purchase gain, the stock can earn back multiple space.

The bear case is just as clear. A company with Globus' history does not need one good quarter to justify a rich multiple; it needs proof that the slower reported pace is temporary. If growth reaccelerates only in adjusted numbers, or if margins improve while the top line stays soft, the market may keep assigning a lower multiple.

What would change the view

• Bullish confirmation: growth ex-Nevro holds or improves while margin gains repeat.
• Bearish confirmation: ex-Nevro growth slips or profitability improvement fails to carry through the next quarter.
• Invalidation: investors keep focusing on the GAAP-versus-non-GAAP split even after the Nevro comparison normalizes.